ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VTGN Vistagen Therapeutics Inc

4.40
-0.15 (-3.30%)
Pre Market
Last Updated: 13:36:43
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vistagen Therapeutics Inc NASDAQ:VTGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -3.30% 4.40 4.40 4.63 1,541 13:36:43

VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference

08/09/2021 1:00pm

GlobeNewswire Inc.


Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Vistagen Therapeutics Charts.

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in Baird’s 2021 Global Healthcare Conference, including a fireside chat with Shawn Singh, Chief Executive Officer, on Tuesday, September 14 at 12:10 p.m. Pacific Time and one-on-one meetings throughout the two-day conference.

A live webcast of VistaGen’s presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com.

About VistaGenVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company Contacts

Media:Mark McPartlandPhone: (650) 577-3606Email: IR@vistagen.com

Investors:Mark FlatherPhone: (650) 577-3617Email: IR@vistagen.com 

 

1 Year Vistagen Therapeutics Chart

1 Year Vistagen Therapeutics Chart

1 Month Vistagen Therapeutics Chart

1 Month Vistagen Therapeutics Chart

Your Recent History

Delayed Upgrade Clock